A biotechnology-focused equity hedge fund based in Western US is looking to invest in therapeutics space. The investment size can vary greatly and the fund is very flexible depending on each company’s needs. The fund is geographically agnostic and looks to invest globally.

The firm is highly interested in biotech therapeutics. The fund is extremely opportunistic in terms of subsectors and indications and will consider companies at all stages of development. The fund recently invested in a European-based company developing small molecule therapeutics for CNS diseases and a US-based company developing therapeutics for oncology.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The fund will require either a board seat or observer status.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm that was formed in 2001 to manage the capital of a successful entrepreneur and a concentrated, select group of other individuals and institutions is seeking to invest into privately held companies in the life science space. Because of the firm’s capital base, they have the ability to be highly flexible and move quickly with investment opportunities. The firm is currently focused on acquiring or investing in outstanding companies, co-investing with debt or equity sponsors, and committing capital to established third-party managers in the private and public markets. The firm can be flexible in terms of investment size and is open to reviewing opportunities from around the globe.

Within the Life Science space, the firm is primarily focused on companies in the healthcare and pharmaceutical services space where the firm has significant experience and expertise. That being said the firm is also open to reviewing early stage companies developing therapeutics, medical device, diagnostics and laboratory equipment. The firm is opportunistic across technology types and indications for these opportunities and will consider companies with products in pre-clinical stage of development to those that already have a product on the market.

The firm is looking for companies with experienced management teams and will seek a board seat on a case by case basis when it is appropriate to do so. The firm is generally more comfortable with co-investing in early stage opportunities although they are not completely opposed to leading a round if the right opportunity were to present itself.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large tech company is actively seeking investments in the life science space. The firm manages two venture funds worth a total of $1.1B; one of these funds focuses on early-stage companies, and the other targets companies of all sizes.  The firm is actively seeking new investment opportunities and is open to review opportunities from around the globe.

In the Life Sciences, the firm seeks to invest in Mobile healthcare IT, bio authentication, fitness and wellness measurement algorithm (i.e. Fitbit and Basis type of companies), calorie measurement, heart measurement, glucose measurement, and medical imaging equipment technology (i.e. Ultrasound, MRI, CAT scan, and image enhancement and distribution tech). The firm is open to reviewing companies of all stages.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital and hedge fund hybrid based in the Western United States is currently looking to make investments into biotech companies. The firm is looking to make investments ranging from $1-5 million generally in Seed and Series A rounds. The firm is open to reviewing opportunities from throughout the United States and Canada.

The firm is currently looking for companies working with therapeutics. The firm is open to reviewing both small molecules and biologics and in terms of indication is focused exclusively on oncology, in particular prostate cancer, and immunology. The firm is open to reviewing company’s at all therapeutic phases of development; however they prefer smaller valuations.

The firm is open to working with public or privately held companies and looks for companies with experienced management teams. The firm looks to add significant value in addition to capital including the expertise and connections of the firm’s partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com